RecruitingPHASE1, PHASE2NCT05181735
Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA
Studying Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Groupe Francophone des Myelodysplasies
- Principal Investigator
- Lionel ADES, Pr.Hôpital Saint Louis
- Intervention
- Luspatercept Injection [Reblozyl](drug)
- Enrollment
- 150 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2029
Study locations (30)
- CHU Amiens-Picardie, Amiens, France
- Clinique de l'Europe, Amiens, France
- CHU Angers, Angers, France
- Centre Hospitalier Victor Dupouy, Argenteuil, France
- CH Henri Duffaut d'Avignon, Avignon, France
- Centre Hospitalier de la Côte Basque, Bayonne, France
- Hôpital Avicenne, Bobigny, France
- Hôpital Privé Sévigné, Cesson-Sévigné, France
- CHU de Grenoble, Grenoble, France
- Centre Hospitalier de Versailles, Le Chesnay, France
- Hôpital Bicêtre, Le Kremlin-Bicêtre, France
- CH Le Mans, Le Mans, France
- CHRU de Lille - Hôpital Claude Huriez, Lille, France
- CHRU de Limoges - Hôpital Dupuytren, Limoges, France
- Centre Hospitalier de Mont de Marsan, Mont-de-Marsan, France
- +15 more locations on ClinicalTrials.gov
Collaborators
Celgene
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05181735 on ClinicalTrials.govOther trials for Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07384715First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)Genmab
- RECRUITINGPHASE1NCT06670222Oral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS)Groupe Francophone des Myelodysplasies
- RECRUITINGPHASE1NCT06552416Safety of MT-401-OTS in Patients With Relapsed AML or MDSMarker Therapeutics, Inc.
- RECRUITINGNANCT07121140Home Blood TransfusionsThomas Jefferson University
- RECRUITINGNANCT05924074Ferroptosis Study in SF3B1-mutant Myelodysplastic Syndromes (FerMDS)University Hospital, Bordeaux
- RECRUITINGNCT06379945Unified platforM for a Better integRal Evaluation of MyeLodyspLastic Syndromes in SpAin-Strategy for Unraveling Personalized genoMic Medicine in Public heAlth System (UMBRELLA-SUMMA)Instituto de Investigación Biomédica de Salamanca
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04798339Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESAH. Lee Moffitt Cancer Center and Research Institute
- RECRUITINGPHASE1NCT04243785A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeEdgewood Oncology Inc.